iBio Inc. (IBIO) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, iBio Inc. (NASDAQ: IBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.81 (+1.17% 1D, market cap $52.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IBIO ranks #968 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBIO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $52.6M) and GANX (Gain Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $51.9M). Among the 5-stock peer group, IBIO leads on earnings multiple (N/A) while IBIO leads on capital efficiency (-35.0% ROIC).
Per IBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001420720), iBio Inc. generated $400.0K in revenue (+77.8% YoY), -$18.4M in net income, and -$15.3M in free cash flow against $64.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While IBIO currently carries a cautious 23/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.08) and Max Pain ($0.85) forces dealer call-delta covering toward $4.01.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
iBio Inc. (IBIO) advanced +1.17% to $0.81, trading at 4% of its 52-week range ($0.69 – $3.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out whether the shares
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +77.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IBIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IBIO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, iBio Inc. (IBIO) ranks #968 by composite RQD confidence (23/100, grade E) and #744 by equity capitalization ($52.3M). Within this direct 5-issuer industry benchmark cohort, IBIO leads on earnings valuation at N/A trailing P/E, while IBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HOWL currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IBIO at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IBIO
ACTIVE
iBio Inc. | E | 23/100 | — | — | -35.0% | +1.17% | $52.3M | Benchmark Subject |
| CNTB Connect Biopharma Holdings Limited | D- | 35/100 | — | — | -35.0% | -1.17% | $52.6M | /cntb-vs-ibio → |
| GANX Gain Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | -0.42% | $51.9M | /ganx-vs-ibio → |
| PLRX Pliant Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -3.35% | $53.3M | /plrx-vs-ibio → |
| HOWL Werewolf Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +3.77% | $53.5M | /howl-vs-ibio → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), iBio Inc. (IBIO) reported GAAP revenue of $400.0K (+77.8% vs. FY2024 revenue of $225.0K ) , GAAP net income of -$18.4M, operating cash flow of -$15.3M, and free cash flow of -$15.3M (+18.4% YoY). On the balance sheet, IBIO closed FY2025 with $64.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $400.0K | -$18.4M | -$15.3M | -$15.3M | $64.4M | — |
| FY2024 (FY) | 2024-06-30 | $225.0K | -$24.9M | -$18.6M | -$18.8M | $21.7M | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$65.0M | -$30.4M | -$30.4M | — | — |
As of 2026-11-02, iBio Inc. (NASDAQ: IBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.81 (+1.17% 1D, market cap $52.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IBIO ranks #968 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBIO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $52.6M) and GANX (Gain Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $51.9M). Among the 5-stock peer group, IBIO leads on earnings multiple (N/A) while IBIO leads on capital efficiency (-35.0% ROIC).
Per IBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001420720), iBio Inc. generated $400.0K in revenue (+77.8% YoY), -$18.4M in net income, and -$15.3M in free cash flow against $64.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IBIO last traded at $0.81 (+1.17% on volume of 248,640 shares), positioning the stock -25.00% below its 50-day simple moving average ($1.08) and -52.07% below its 200-day simple moving average ($1.69). Across its 52-week range of $0.69 to $3.82, IBIO sits at the 3.8% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.91).
Why IBIO Stock advanced +1.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).